Beyond Air Sales Jump 158 Percent
Beyond Air (NASDAQ:XAIR), a medical device company focused on nitric oxide therapies, released its Q1 fiscal 2026 results on August 18, 2025. The key highlight was a 157% rise in GAAP revenue compared to the prior-year quarter, reaching $1.8 million. However, this result missed analyst estimates, which were set at $2.48 million. Earnings per share were $(1.53), short of expectations for a narrower $(0.96) GAAP loss, but improved from the prior year’s GAAP $(5.32) per share result. The quarter featured notable international sales for the first time, expanding global hospital placements and progress on regulatory submission for next-generation products. Despite these gains and sizable reductions in operating expenses, the quarter saw a larger net loss (GAAP) than forecasted, and cash reserves tightened, raising near-term liquidity questions.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report.
Beyond Air (NASDAQ:XAIR) is a medical technology company developing and commercializing systems that generate and deliver nitric oxide gas for use in hospitals. Its central platform is the LungFit product family, which generates nitric oxide from ambient air for respiratory treatments, eliminating the traditional need for high-pressure gas cylinders. The company’s products target conditions like persistent pulmonary hypertension in newborns and severe lung infections, and its pipeline extends to oncology and neurological disorders.
Source Fool.com
